一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
吸烟史预测 PD-L1 表达阴性非小细胞肺癌患者中 TILs 高存在及 PD-1 阻断疗效
英文原题：Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
查看英文原题
Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究思路按摘要原文分段
背景
肿瘤细胞上程序性死亡配体1（PD-L1）的表达是程序性细胞死亡1（PD-1）阻断治疗的预测性生物标志物。本研究旨在阐明nivolumab在PD-L1表达阴性的非小细胞肺癌（NSCLC）患者中疗效的预测因素。
方法
我们回顾性分析了2016年1月至2019年4月间晚期NSCLC患者的病历，并探究了nivolumab的预测标志物，包括CD8+TIL（肿瘤浸润淋巴细胞）（TILs）的状态。
结果
共纳入70例NSCLC患者。重度吸烟史患者（吸烟指数：SI≥600）的总体缓解率（ORR）和无进展生存期（PFS）优于无重度吸烟史患者（SI<600）[ORR：20.6% vs. 2.8%，（p=0.02）；PFS：2.4个月 vs. 1.8个月，（p=0.04）]。高密度CD8 + TIL与重度吸烟史显著相关（p=0.04）。结论：重度吸烟史（SI≥600）与大量CD8 + TIL相关，可能是nivolumab在PD-L1表达阴性肿瘤NSCLC患者中疗效的预测因素。
展开英文摘要原文
PATIENTS AND METHODS
We retrospectively reviewed the records of advanced NSCLC patients between January 2016 and April 2019, and investigated the predictive marker of nivolumab including the status of CD8 + tumor infiltrating lymphocytes (TILs).
RESULTS
A total of 70 NSCLC patients were included. Overall response rate (ORR) and progression-free survival (PFS) were better in patients with a heavy smoking history (smoking index: SI≥600) than in those without (SI<600) [ORR: 20.6% vs. 2.8%, (p=0.02), and PFS: 2.4 months vs. 1.8 months, (p=0.04)]. A high density of CD8 + TILs was significantly associated with a heavy smoking history (p=0.04). Conlusion: Heavy smoking history (SI≥600), which was correlated with a large number of CD8 + TILs, could be a predictor of the efficacy of nivolumab in NSCLC patients with PD-L1 expression-negative tumors.
论文信息
- 作者
- Shimoda Y、Yoshida T、Shirasawa M、Mizuno T、Jo H、Matsumoto Y、Shinno Y、Okuma Y
- 第一作者单位
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.Japan
- 通讯作者单位
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; tatyoshi@ncc.go.jp.Japan
- 文献类型
- 对照研究
- 期刊
- Anticancer research2021 Nov
- 原文标识
- PubMed 34732447 · DOI 10.21873/anticanres.15390